Ultralow-Dose Micronized 17β-Estradiol and Bone Density and Bone Metabolism in Older Women: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 8, 2003, Pages 1042-1048

  Prestwood, Karen M ^a   Kenny, Anne M ^a   Kleppinger, Alison ^a   Kulldorff, Martin ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; ESTRADIOL; ESTRONE; PLACEBO; PROGESTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; BIOLOGICAL MARKER;

AGED; ARTICLE; BLOATING; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; FEMUR NECK; FLUID RETENTION; HEADACHE; HIP; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINE; WRIST; BONE REMODELING; DRUG EFFECT; RADIODENSITOMETRY;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0041920903     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.8.1042     Document Type: Article

References (22)

1. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progesterone in healthy postmenopausal women. JAMA. 2002;288:321-333.
2. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16.
3. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short-term effects of conjugated equine estrogen on bone turnover in older women. J Clin Endocrinol Metab. 1994;79:366-371.
4. Villareal DT, Binder EF, Wiliams DB, et al. Bone mineral density response to estrogen replacement therapy in frail elderly women. JAMA. 2001;286:815-820.
5. Prestwood KM, Thompson DL, Kenny AM, Seibel MJ, Pilbeam CC, Raisz LG. Low dose estrogen and calcium have an additive effect on bone resorption in older women. J Clin Endocrinol Metab. 1999;84:179-183.
6. Recker RR, Davies KM, Dowd RM, Heaney R. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med. 1999;130:897-904.
7. Prestwood KM, Kenny AM, Unson C, Kulldorff M. The effect of low dose micronized 17β-estradiol on bone turnover, sex hormone levels, and side effects in older women. J Clin Endocrinol Metab. 2000;85:4462-4469.
8. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The Physical Activity Scale for the Elderly (PASE). J Clin Epidemiol. 1999;52:643-651.
9. Ettnger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med. 1987;106:40-45.
10. Ettinger B, Genant HK, Steiger PM, Madvig P. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol. 1992;166:479-488.
11. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy. Arch Intern Med. 1997;157:2609-2615.
12. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogen with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
13. Mizunuma H, Okano H, Soda M, Kagami I, et al. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy. Maturitas. 1997;27:69-76.
14. Wells G, Tugwell P, Shea B, et al. Meta-analysis of therapies for postmenopausal osteoporosis, V. Endocr Rev. 2002;23:529-539.
15. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal 17β-estradiol. Ann Intern Med. 1992;117:1-9.
16. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637-645.
17. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344-1352.
18. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med. 1995;333:1437-1443.
19. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.
20. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip fracture and vertebral fractures among older women. N Engl J Med. 1998;339:733-738.
21. Ettinger B, Pressman A, Skalrin P, et al. Associations between low levels of serum estradiol, bone density, and fractures among elderly women. J Clin Endocrinol Metab. 1998;83:2239-2243.
22. Stone K, Bauer D, Black DM, et al. Hormonal predictors of bone loss in elderly women. J Bone Miner Res. 1998;13:1167-1174.